Edwards Lifesciences Presents New Data On EVOQUE Transcatheter Tricuspid Valve Replacement System

Edwards Lifesciences (NYSE: EW) presented new data on its EVOQUE transcatheter tricuspid valve replacement (TTVR) system at the ACC.26 conference, highlighting significant patient benefits such as near elimination of tricuspid regurgitation and improved health status. The TRISCEND II trial results indicate no added device-related risks and a reduction in all-cause mortality when accounting for patient crossover. These findings build on previous results shared at the ESC 2025 congress.